000 | 01897 a2200529 4500 | ||
---|---|---|---|
005 | 20250513031640.0 | ||
264 | 0 | _c19950531 | |
008 | 199505s 0 0 eng d | ||
022 | _a0006-4971 | ||
040 |
_aNLM _beng _cNLM |
||
100 | 1 | _aD'Hondt, V | |
245 | 0 | 0 |
_aThrombopoietic effects and toxicity of interleukin-6 in patients with ovarian cancer before and after chemotherapy: a multicentric placebo-controlled, randomized phase Ib study. _h[electronic resource] |
260 |
_bBlood _cMay 1995 |
||
300 |
_a2347-53 p. _bdigital |
||
500 | _aPublication Type: Clinical Trial; Clinical Trial, Phase I; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't | ||
650 | 0 | 4 |
_aAcute-Phase Proteins _xbiosynthesis |
650 | 0 | 4 | _aAdult |
650 | 0 | 4 |
_aAntineoplastic Combined Chemotherapy Protocols _xadverse effects |
650 | 0 | 4 |
_aBone Marrow _xpathology |
650 | 0 | 4 |
_aCarboplatin _xadministration & dosage |
650 | 0 | 4 |
_aCyclophosphamide _xadministration & dosage |
650 | 0 | 4 | _aFemale |
650 | 0 | 4 |
_aFever _xchemically induced |
650 | 0 | 4 |
_aHeadache _xchemically induced |
650 | 0 | 4 | _aHumans |
650 | 0 | 4 |
_aImmunologic Factors _xadverse effects |
650 | 0 | 4 |
_aInterleukin-6 _xadverse effects |
650 | 0 | 4 |
_aMegakaryocytes _xdrug effects |
650 | 0 | 4 | _aMiddle Aged |
650 | 0 | 4 |
_aOvarian Neoplasms _xblood |
650 | 0 | 4 |
_aPlatelet Count _xdrug effects |
650 | 0 | 4 | _aPloidies |
650 | 0 | 4 | _aPremedication |
650 | 0 | 4 |
_aRecombinant Proteins _xadverse effects |
650 | 0 | 4 | _aSafety |
650 | 0 | 4 |
_aThrombocytopenia _xchemically induced |
700 | 1 | _aHumblet, Y | |
700 | 1 | _aGuillaume, T | |
700 | 1 | _aBaatout, S | |
700 | 1 | _aChatelain, C | |
700 | 1 | _aBerlière, M | |
700 | 1 | _aLongueville, J | |
700 | 1 | _aFeyens, A M | |
700 | 1 | _ade Greve, J | |
700 | 1 | _aVan Oosterom, A | |
773 | 0 |
_tBlood _gvol. 85 _gno. 9 _gp. 2347-53 |
|
999 |
_c7536568 _d7536568 |